Worldwide | PharmaShots

Sangamo Highlights its Genomic Medicine Pipeline at R&D Day 2019

Sangamo Signs a Worldwide License Agreement with Novartis to Develop Genomic Therapies for Three Neurodevelopmental Targets

July 30, 2020July 30, 2020Shiwani Sharma

Shots: Sangamo to receive $75M upfront within 30 days, $720M milestone payments including up to $420M in development milestones and up to $300M [Read More...]

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop Imlifidase for Duchenne Muscular Dystrophy and Limb-Girdle Muscular Dystrophy

July 3, 2020July 3, 2020Tuba Khan

Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy [Read More...]

AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101

June 19, 2020June 19, 2020Tuba Khan

Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales [Read More...]

AstraZeneca Signs Exclusive Worldwide License Agreement with Accent for RMP-Targeting Therapies

June 4, 2020June 5, 2020Tuba Khan

Shots: Accent to receive $55M upfront and $1.1B as co-development option and milestone payment, plus royalties and profit split based on the option [Read More...]

AbbVie Signs a Worldwide License Agreement with Jacobio to Advance SHP2 Inhibitors

June 1, 2020June 5, 2020Tuba Khan

Shots: AbbVie to get an exclusive global license to develop and commercialize JAB-3068 and JAB-3312 from Jacobio AbbVie will provide undisclosed R&D cost [Read More...]

Roche Reports Results of Risdiplam in Pivotal SUNFISH Study for Patients with Type 2 or 3 Spinal Muscular Atrophy

Roche Signs an Exclusive Worldwide Option and License Agreement with Vividion Focusing on Novel E3 Ligases

May 19, 2020May 19, 2020Tuba Khan

Shots: Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties [Read More...]

Recursion Signs a Worldwide License Agreement with Takeda to Develop TAK-733 for Hereditary Cancer Syndrome

May 15, 2020May 15, 2020Tuba Khan

Shots: Recursion to get exclusive WW rights to develop and commercialize TAK-733 for the treatment of a hereditary cancer syndrome and related areas [Read More...]

Moderna Signs a Ten-Year Worldwide Agreement with Lonza to Manufacture mRNA-1273 Against COVID-19

May 1, 2020May 1, 2020Tuba Khan

Shots: :stohththShots: The companies intend to establish manufacturing suites at Lonza’s facilities in the US and Switzerland to manufacture mRNA-1273 at both sites. [Read More...]

AstraZeneca Signs a Worldwide Development and Distribution Agreement with Oxford University for Vaccine Against COVID-19

April 30, 2020June 5, 2020Tuba Khan

Shots: The collaboration will bring Oxford’s recombinant adenovirus vaccine, ChAdOx1 nCoV-19 to the patients and will enable AstraZeneca to be responsible for the [Read More...]

Janssen Signs a Worldwide Collaboration with Fate Therapeutics for Novel iPSC-Derived Cell-Based Cancer Immunotherapies

April 6, 2020April 7, 2020Tuba Khan

Shots: Fate to receive $50M up front and $50M equity investment at $31/ share and funding for the research and development of collaboration [Read More...]